Theratechnologies (OTCMKTS:THERF) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Theratechnologies (OTCMKTS:THERF) from a sell rating to a hold rating in a report issued on Monday, April 2nd.

Shares of OTCMKTS:THERF traded down $0.01 during midday trading on Monday, hitting $7.35. The company had a trading volume of 89,455 shares, compared to its average volume of 59,812. Theratechnologies has a twelve month low of $3.90 and a twelve month high of $7.84. The company has a quick ratio of 1.30, a current ratio of 1.76 and a debt-to-equity ratio of 0.10.

How to Become a New Pot Stock Millionaire

Theratechnologies (OTCMKTS:THERF) last posted its quarterly earnings results on Thursday, April 5th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. Theratechnologies had a negative return on equity of 35.83% and a negative net margin of 34.43%. The firm had revenue of $8.12 million during the quarter.

TRADEMARK VIOLATION WARNING: “Theratechnologies (OTCMKTS:THERF) Stock Rating Upgraded by ValuEngine” was first published by Macon Daily and is the property of of Macon Daily. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.

Leave a Reply